Stocktoria

Natera, Inc. NTRA

Nasdaq · stock · Services-Medical Laboratories · website · IPO 2015-07-02 · LEI

Natera, Inc. (NTRA) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $2.3B at a -9.0% net margin.

Chart by TradingView
30/100
Stocktoria Quality Score · grade D
3/9
Piotroski F — financial health
0.87
Altman Z″ — distress risk · distress
Dividend yield · no dividend

Quality score trend · recomputed for each fiscal year

Piotroski F /9
2 1 3 3 2 3 3 5 4 3 2016201720182019202020212022202320242025
Altman Z″
-4.71 -8.58 -6.62 -0.43 1.01 -0.41 -1.83 -1.94 0.83 0.87 2016201720182019202020212022202320242025

Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.

$315.96 as of 2026-08-01 · +87.8% 1y
$160.97$315.9652-wk
Market cap USD$37.5B
Net margin 5y avg-40.5%
Return on equity 5y avg-46.9%
Beta1.51
Employees6,135

Analyst price target

$316.95 +0.3% vs last
consensus: buy · 20 analysts
target range $193.00 – $375.00 · median $330.00
5 strong buy · 13 buy · 3 hold
Recent analyst actions
DateFirmRating
2026-08-12Piper SandlerOverweight (main)
2026-08-12Stephens & Co.Overweight (main)
2026-08-12GuggenheimBuy (main)
2026-08-07TD CowenBuy (main)
2026-08-07CitigroupBuy (main)
2026-08-07RBC CapitalOutperform (main)

Wall Street analyst consensus — a sentiment gauge, not our scoring.

Forward estimates · earnings calendar →

Forward EPS est.$-0.11

Consensus analyst estimates and scheduled dates — forward-looking, may change.

Revenue trend · last 10y · up

How it ranks in Services · percentile among 982 companies

Piotroski Fstronger than 20%
Net marginstronger than 38%
Return on equitystronger than 35%
Revenue growthstronger than 91%

Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.

Piotroski F breakdown · 3/9 tests passed

Altman Z″ components · distress zone

ComponentValue
Working capital / assets0.44
Retained earnings / assets-1.157
EBIT / assets-0.129
Equity / liabilities2.496

Sector peers · similar-size Services companies compare side by side →

TickerCompanyPiotroski FAltman Z″P / ERevenue growth
NTRANatera, Inc.3/90.87+35.9%
RDNTRadNet, Inc.3/91.4+11.5%
FTREFortrea Holdings Inc.3/9-3.58+1%
GHGuardant Health, Inc.4/9-2.57+32.9%
VCYTVERACYTE, INC.7/915.6661.2+16%
CDNACareDx, Inc.4/90.16+13.8%
CSTLCASTLE BIOSCIENCES INC3/96.15+3.7%

All Services companies →

About Natera, Inc.

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company has a collaboration with Diakonos Oncology Corp. to assess molecular response in patients with refractory melanoma. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.

FAQ

Is NTRA financially healthy?

Natera, Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.

Does NTRA pay a dividend?

No, Natera, Inc. does not currently pay a dividend.

How profitable is NTRA?

In FY2025, Natera, Inc. had a net margin of -9.0% and a return on equity of -12.2%.

What is the analyst price target for NTRA?

The average Wall-Street price target for Natera, Inc. is $316.95, about 0.3% above the recent price, from 20 analysts (consensus: buy).

Is NTRA a good stock to buy?

Stocktoria doesn't give buy or sell advice, but here is the data on Natera, Inc.: a Piotroski F-score of 3/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.